DENVER, Colo., Nov 8, 2023 (www.247marketnews.com)- HCW Biologics Inc (NASDAQ: HCWB) stated that data from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”).
HCW Biologics is trading at $1.73, up $0.13 (+8.12%) on 272K premarket shares.
Its 52-week range is $1.08 to $2.35. This morning’s premarket volume is way larger than its typical daily volume, so this could make a nice run today.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
